The Probable Suspect in the Prediction of Relapse in Acute Leukemia: Thrombocytopenia

• Published in: Van Tıp Dergisi Vol. 29; no. 1; pp. 27 - 35
• Main Authors: İpek Dokurel Çetin, Nihal Özdemir, Tülin Tiraje Celkan, Sarper Erdogan, Hilmi Apak
• Format: Journal Article
• Language: English
• Published: Van Yuzuncu Yil University, School of Medicine 01-01-2022
• Subjects: acute leukemia; child; relapse; thrombocytopenia
• ISSN: 2587-0351
• DOI: 10.5505/vtd.2022.17092

INTRODUCTION: Relapse is not common in patients with acute leukemia in childhood, however it is a serious complication with high mortality rate. We aimed to predict relapse among pediatric acute leukemia patients in remission by using complete blood parameters which are used routinely in clinical practice. METHODS: In all,279 children diagnosed with acute leukemia over a 20-year period were retrospectively reviewed. Fourty two children relapsed and 37 children non-relapsed acute leukemia cases, all of whose data were available, were included in the study. Blood count parameters and physical examination findings at the time of diagnosis and during the follow-up were evaluated retrospectively in all patients. RESULTS: In the relapse group;children were diagnosed with B-cell ALL(n=24), T-cell ALL(n=10), and AML(n=8). In non- relapse group;children were diagnosed with B-cell ALL(n=26), T-cell (n=10) and AML(n=1).Thrombocytopenia was observed in 24 patients for the relapse group, compared to nine children in non- relapse group. After remission, the risk of relapse was significantly higher in patients with thrombocytopenia (p= 0.003) than in patients without thrombocytopenia among both groups. During the remission period, relapse was observed in all patients with thrombocytopenia lasting for an average of 3.86 weeks. DISCUSSION AND CONCLUSION: Thrombocytopenia during the remission period of pediatric acute leukemia patients can be explained primarily by the effect of chemotherapeutic drugs used in treatment and possible infections on the bone marrow. We demonstrated that the presence of thrombocytopenia which develops after the remission period and lasts longer than three weeks can be used as an easy-to-access blood parameter in the prediction of relapse.